Novo Nordisk is a Danish pharmaceutical company that created a weight-loss drug called Wegovy. The demand for the drug has increased after it was approved by the FDA and released on the U.S market. The shortage problems might be resolved by next year. The company’s sales increased by 15% in comparison with 2020.
The clinical trials were successful, and the drug is efficient and safe
During the clinical trials, Wegovy drug managed to reduce the body weight of obese people by 15% in one year. This massive weight loss has not been accomplished by other weight-loss drugs on the market. This means that for now, it could be the most efficient one that could save people from bariatric surgery.
According to sources, the drug has an ingredient known as semaglutide. This active ingredient is also used in diabetes drugs. The ingredient acts as a GLP-1 hormone, the one responsible for regulating our metabolism and hunger sensation. The active ingredient can remain for a longer period of time in our bodies than the natural hormone.
All weight-loss drugs should be used after talking to a doctor
Because it is a medical treatment to fight chronic obesity, it is best to talk to a health provider before deciding to take it. The drug can be administered once a week via injection. The FDA approved it a couple of months ago, and since it became popular due to its wonderful results.
Some common side effects of the active ingredient could include diarrhea, vomiting, nausea, pain in the abdominal area, headaches and fatigue, indigestion, and constipation. Some mention they are most common during the first weeks. Some people with pre-existing health conditions might not be advised to use it.
This next-generation weight loss drug might become the road opener we were all waiting for, especially those struggling with obesity for many years.